Table 1. Patients’ characteristics.
| Hemodialysis (n = 42) | Hemodiafiltration (n = 18) | p-value | |
|---|---|---|---|
| Demographics | |||
| Age, years (IQR) | 67.5 (57.0–78.0) | 56.0 (50.0–70.0) | 0.025 |
| Female | 22 (52.4%) | 9 (50.0%) | >0.999 |
| Body mass index, kg/m2 (IQR) | 22.7 (20.1–26.4) | 24.6 (20.0–27.0) | 0.580 |
| Dialysis vintages, years (IQR) | 3.9 (3.1–6.6) | 5.3 (3.5–10.5) | 0.095 |
| ESRD causes | |||
| Diabetic nephropathy | 24 (57.1%) | 6 (33.3%) | 0.158 |
| Hypertensive nephropathy | 13 (31.0%) | 10 (55.6%) | 0.089 |
| Glomerulonephritis | 2 (4.8%) | 1 (5.6%) | >0.999 |
| Polycystic kidney disease | 2 (4.8%) | 1 (5.6%) | >0.999 |
| Others | 3 (7.1%) | 2 (11.1%) | 0.631 |
| Underlying diseases | |||
| Diabetes mellitus | 27 (64.3%) | 7 (38.9%) | 0.091 |
| Hypertension | 40 (95.2%) | 18 (100.0%) | >0.999 |
| Dyslipidemia | 24 (57.1%) | 11 (61.1%) | >0.999 |
| CAD | 12 (28.6%) | 4 (22.2%) | 0.755 |
| Congestive heart failure | 4 (9.5%) | 2 (11.1%) | >0.999 |
| Atrial fibrillation | 3 (7.1%) | 0 (0.0%) | 0.547 |
| CVA | 5 (11.9%) | 0 (0.0%) | 0.309 |
| COPD | 2 (4.8%) | 0 (0.0%) | >0.999 |
| Cirrhosis | 1 (2.4%) | 0 (0.0%) | >0.999 |
| Chronic hepatitis B | 2 (4.8%) | 1 (5.6%) | >0.999 |
| Malignancy | 3 (7.1%) | 1 (5.6%) | >0.999 |
| Intra-HD hypotension on day 0 | 5 (12.2%) | 3 (16.7%) | 0.690 |
| Kt/Vurea | 1.9 (1.6–2.2) | 1.7 (1.6–2.1) | 0.577 |
| Medication | |||
| Iron | 16 (38.1%) | 10 (55.6%) | 0.261 |
| Erythropoietin dose, IU/week | 8,000 (6,000–12,000) | 6,000 (5,000–10,000) | 0.266 |
| Statin | 23 (56.1%) | 12 (66.7%) | 0.568 |
| Laboratory parameters | |||
| Hemoglobin, g/dL | 10.6 (9.9–11.5) | 11.0 (10.4–11.7) | 0.269 |
| White blood cells, /mm3 | 6.4 (5.2–8.1) | 6.5 (5.4–7.0) | 0.872 |
| Platelets, /mm3 | 184.5 (153.0–232.0) | 179.5 (147.0–212.0) | 0.910 |
| Blood urea nitrogen, mg/dL | 55.5 (45.0–68.0) | 77.0 (62.0–84.0) | 0.009 |
| Creatinine, mg/dL | 9.2 (7.5–10.8) | 11.0 (8.6–13.8) | 0.028 |
| Hemoglobin A1c, % | 5.6 (5.1–7.0) | 6.5 (5.5–7.7) | 0.345 |
| Sodium, mmol/L | 138.0 (136.0–140.0) | 139.0 (137.0–139.0) | 0.284 |
| Potassium, mmol/L | 4.4 (4.1–4.6) | 4.6 (4.1–5.2) | 0.238 |
| Chloride, mmol/L | 97.0 (95.0–99.0) | 97.0 (96.0–99.0) | 0.394 |
| Bicarbonate, mmol/L | 22.0 (20.0–23.0) | 21.5 (20.0–24.0) | 0.639 |
| Calcium, mg/dL | 8.7 (8.4–9.0) | 9.0 (8.4–9.2) | 0.405 |
| Phosphate, mg/dL | 4.1 (2.9–5.4) | 4.9 (3.4–5.2) | 0.345 |
| Albumin, g/dL | 3.6 (3.3–3.9) | 3.4 (3.2–3.5) | 0.106 |
| LDL-C, mg/dL | 88.5 (60.0–105.0) | 95.0 (54.0–104.0) | 0.955 |
| Triglyceride, mg/dL | 105.0 (78.0–155.0) | 104.5 (79.0–127.0) | 0.968 |
| iPTH, pg/mL | 416.0 (197.0–566.0) | 318.5 (144.0–614.0) | 0.542 |
| Ferritin, ng/mL | 458.0 (253.0–708.0) | 365.5 (260.0–540.0) | 0.223 |
| Transferrin saturation, % | 27.0 (21.0–34.0) | 24.7 (23.0–32.0) | 0.458 |
| Beta 2 microglobulin, mcg/mL | 23.0 (19.1–28.2) | 22.3 (19.2–24.4) | 0.329 |
| C-reactive protein, mg/dL | 0.31 (0.10–0.75) | 0.18 (0.10–0.36) | 0.482 |
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESRD, end-stage renal disease; HD, hemodialysis; iPTH, intact parathyroid hormone; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol level; RRT, renal replacement therapy